Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

SILVER SPRING, Md., Oct. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal.  These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm.  

The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate.

"Ferriprox represents the first new FDA-approved treatment for this disorder since 2005," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Ferriprox is based on an analysis of data from twelve clinical studies in 236 patients. Patients participating in the study did not respond to prior iron chelation therapy.  Ferriprox was considered a successful treatment for patients who experienced at least a 20 percent decrease in serum ferritin, a protein that stores iron in the body for later use. Half of the patients in the study experienced at least a 20 percent decrease in ferritin levels.

The most common side effects seen in patients who received Ferriprox included nausea, vomiting, abdominal and joint pain, urine discoloration (chromaturia), a decrease in the number of white blood cells (neutropenia), and an increase in
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DUBLIN , Nov. 26, 2014  Perrigo Company ... leading global provider of "Quality Affordable Healthcare Products®," today ... offering relating to the sale of 6,809,210 ordinary shares ... including the full exercise of the option to purchase ... Morgan Securities LLC and Barclays Capital Inc., as representatives ...
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... Scott Steiger lives in St. ... an engineer for the past 20 years, he,s traveled extensively and ... He,s been to six of the seven continents. Travel is a ... http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 So ... pretty good idea of what,s required. His latest creation ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2
... by experts to be important for cervical cancer ... data from an,extended follow-up study show that GlaxoSmithKline ... generates sustained high levels of,neutralizing antibodies against the ... up to 6.4 years. This is the longest,duration ...
... American Society of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative ... a regimen of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of ...
Cached Medicine Technology:CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7
(Date:11/28/2014)... An inventor and dental assistant from Kent, Wash., ... and it was almost impossible to reach. "This gave me ... , The patent-pending Access Light allows for easier use of ... the mouth, as well as avoids harm to the lips, ... use and clean, it also helps prevent cross-contamination. , The ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 A newly ... provides an overview of the influenza virus that will soon ... season. , The article begins with a brief explanation ... its symptoms. It reminds families that children under the age ... suffering from chronic diseases, such as heart and lung diseases, ...
(Date:11/28/2014)... "Most of my life, I have suffered from ... an inventor from Findlay, Ohio. "I thought that there had ... foot, which inspired me to invent this accessory." , She ... to support an injured foot. The sling makes it easier ... for crutches. The design redistributes weight so that the individual ...
(Date:11/28/2014)... TN (PRWEB) November 28, 2014 ARTAS ... Tennessee for the first time. PAI Medical Group hair ... will be performing a robotic hair transplant procedure in ... 9:00 A.M. , The first in Tennessee and one ... Medical Group now offers ARTAS robotic hair transplantation. Patients ...
(Date:11/28/2014)... Nipomo Family Dentistry , founded ... opened its doors at 195 N. Thompson St., Suite ... care like teeth cleanings, oral exams, fillings, implants and ... whitening (and Kor whitening), laser whitening, gum tissue treatment, ... Dentistry’s five-person team also takes a philanthropic approach to ...
Breaking Medicine News(10 mins):Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 3
... choice of drug for patients suffering from prostate cancer may ... the Scottish Medicines Consortium (SMC) is of the view that ... much effect on prostate cancer making it an expensive not ... the drug feel that the drug had shown very good ...
... of the main causes of tooth loss worldwide and ... extractions (those with periodontal disease lost 2.8 teeth versus ... has now been found out from research that certain ... than others. ,The study analyzed the effects ...
... sinus tumors can be removed through the nose using endoscopy ... ,With this approach, doctors use tiny scopes and ... a device that pulverizes and suctions. At points where the ... and a diamond drill is used to eliminate tumor cells ...
... appears in the October issue of the journal ... early exposure to severe hypoglycemia during development negatively ... is a significant and relatively common complication of ... Repeated severe hypoglycemia has been reported to reduce ...
... Minister Anbumani Ramadoss has said that the government is very ... plans to take several steps to check female foeticide, which ... Ramadoss said that there were plans to set up surveillance ... practice that prevails on a large scale in the country. ...
... new research shows that in Children with neurological ... respiratory failure ,if they're hospitalized with influenza.// ... Journal of the American Medical Association, are based on ... influenza at The Children's Hospital of Philadelphia over four ...
Cached Medicine News:Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 2Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 3Health News:Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus 2Health News:Severe Hypoglycemia And Spatial Memory In Children With Type 1 Diabetes 2
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
Medicine Products: